Author + information
- Min Gyu Kanga,b,
- Jong-Hwa Ahna,b,
- Jeong Yoon Janga,b,
- Hyun Woong Parka,b,
- Jin-Sin Koha,b,
- Jeong-Rang Parka,b,
- Yongwhi Parka,b,
- Seok-Jae Hwanga,b,
- Choong Hwan Kwaka,b,
- Jin-Yong Hwanga,b and
- Young-Hoon Jeonga,b
Background: Recovery of LV function following AMI is associated with the risk of long-term CV mortality and CHF progression. We sought to evaluate the predictors of recovery of LV function in AMI patients.
Methods: AMI patients treated with uneventful PCI were prospectively enrolled (n=224). At 30-day follow-up, biochemical measurements (including NT-proBNP) and platelet reactivity (PRU) by VerifyNow were performed. Good recovery of LV function was defined using age-adjusted NT-proBNP cutoff values (ESC criteria).
Results: “High NT-proBNPfollow-up” was observed in 52 patients (20.6%). Compared with clopidogrel treatment, ticagrelor treatment decreased the level of NT-proBNPfollow-up (672±1091 vs. 1695±4873 pg/ml; p= 0.030). Multivariate analysis showed that ticagrelor vs. clopidogrel significantly reduced the risk of “high NT-proBNPfollow-up” by about 55% (95% CI: 0.21 – 0.95; p= 0.037). By ROC curve analysis, PRUfollow-up ≥ 160 (4.3% on ticagrelor vs. 71.6% on clopidogrel) was the optimal cutoff of “high NT-proBNPfollow-up” (AUC: 0.60; 95% CI: 0.51 – 0.69: p= 0.026). After adjustment, “PRUfollow-up ≥ 160” increased the risk of “high NT-proBNPfollow-up” by about 3-fold (95% CI: 1.33 – 6.54; p= 0.008).
Conclusions: This is the first to suggest the impact of ticagrelor on recovery of LV function in AMI patients, which is mostly related with the level of platelet inhibition. The linkage of this effect with long-term clinical outcome will be evaluated in the large-scale clinical trials.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Antithrombotic Therapy in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1252-314
- 2017 American College of Cardiology Foundation